The Inflammatory Study (MAD cohort)
In this clinical trial, we will assess how the study drug is metabolised in the bodies of healthy volunteers who have not been diagnosed with IBD.
This study is to investigate Adrenomedullin (AM) which is a vasodilatory peptide hormone, as a potential new treatment for inflammatory bowel disease (IBD). IBD is an unexplained inflammation of the bowl that causes symptoms such as diarrhoea, pain and fatigue. It is hoped that AM could help reduce inflammatory symptoms and regenerate tissues and cells that are damaged by IBD.
The study drug is an IV infusion of AM which is responsible for a number of functions in the body, including wound healing, blood vessel dilation, and hormone secretion. It also helps the body to regulate its immune system by eliminating foreign substances that enter the body.
The trial has been approved by an independent ethics committee and eligible participants will be reimbursed for their time.
Call us on 1800 243 733 to discuss your eligibility today!